Lundbeck CSO: Label expansion will ease communication
FDA has accepted Lundbeck’s application for a label expansion for antidepressant Brintellix detailing its cognitive effects. The announcement has no impact on the Danish group’s peak-sales estimate for the drug, but it does ease communication with doctors and patients, says Lundbeck’s science chief.
BY LONNI LYNGE
Lundbeck and its big pharma partner, Japan-based Takeda, might have moved one step closer to securing a label expansion for antidepressant Brintellix on the important US market, as the FDA has accepted a supplemental New Drug Application from the groups, Lundbeck writes in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Promising signs from Lundbeck’s depression drug
For abonnenter
Kåre Schultz to present Lundbeck plan this year
For abonnenter
Lundbeck CSO: It will have a huge impact
For abonnenter
